BioNTech announced an all-stock acquisition of CureVac valued at $1.25 billion, consolidating leadership in mRNA technology and expanding cancer immunotherapy capabilities. The deal, which offers CureVac shareholders a 55% premium, focuses on technological integration rather than product pipelines, marking a major milestone in BioNTech’s oncology strategy and resolving ongoing patent litigation.